GSK has halted all shipments of ARIXTRA Starter Kits containing the Triad For important product information, log onto Arixtra mg/ ml solution for injection, pre-filled syringe. 2. .. Detailed information on this medicinal product is available on the website of the European . Arixtra is a medicine that helps prevent blood clots from forming in the blood This medicinal product contains less than 23 mg of sodium in each dose and.

Author: Kazralkis Dushakar
Country: Norway
Language: English (Spanish)
Genre: Love
Published (Last): 14 April 2007
Pages: 171
PDF File Size: 19.16 Mb
ePub File Size: 6.81 Mb
ISBN: 878-2-27093-155-4
Downloads: 47079
Price: Free* [*Free Regsitration Required]
Uploader: Felar

Initiate concurrent warfarin as soon as possible, 1 usually within 72 hours of fondaparinux injection; 1 20 ACCP recommends initiating warfarin simultaneously on the first day of fondaparinux treatment. iformation

Consider potential benefits versus risks of spinal or epidural anesthesia or spinal puncture in patients receiving or being considered for thromboprophylaxis with anticoagulants. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Bridgewater, Infomation Jul. FDA alerts for all medications. Arixtra Rating 5 User Reviews 8.

Discontinue oral anticoagulants prior to initiation of fondaparinux 1 40 If coadministration is essential, monitor patients closely 1 History of serious hypersensitivity reaction e.

Prescribng Appl Thromb Hemost. Increased risk of hemorrhage; closely monitor for signs and symptoms of bleeding. Patients should be sitting or supine during administration. Anticoagulant effects may persist for 2—4 days following discontinuance of therapy in patients with normal renal function i.

Patients undergoing hip-fracture, hip- or knee-replacement surgery: Risk increased by use of indwelling epidural catheters or by concomitant use of drugs affecting hemostasis e.

Usual duration of therapy is 5—9 days, 1 3 4 5 6 although up to 11 days has been studied in clinical trials of orthopedic surgery. Used for extended prophylaxis i. Discontinue platelet-aggregation inhibitors prior to initiation of fondaparinux 1 40 If coadministration is essential, monitor patients closely 1 In general, pharmacologic thromboprophylaxis is recommended only in such patients considered to be at high risk of venous thromboembolism.


Monitor frequently for manifestations of neurologic impairment and treat urgently if neurologic compromise noted. If fondaparinux therapy is to be continued after hospital discharge, importance of instructing patient on proper administration of the drug, including injection technique. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: The activity of fondaparinux sodium is measured based on plasma drug concentrations quantified by anti-factor Xa activity using fondaparinux as the calibrator.

Print this page Add to My Med List. Anticoagulation results from rapid inhibition of factor Xa by antithrombin III bound to fondaparinux about fold greater than innate activity. A randomized double-blind trial. Postoperative wound infection, postoperative hemorrhage, fever, surgical site reaction, anemia, hypertension, pneumonia, vomiting.

Mylan Worldwide

Active major bleeding, bacterial endocarditis, or thrombocytopenia associated with a positive in vitro test for antiplatelet antibody HIT in the presence of the drug. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Usual duration of therapy is 5—9 days, although up to 10 days has been studied. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.

Extended thromboprophylaxis for prescriving to 35 days is recommended in patients undergoing hip fracture surgery, 40 and suggested for patients undergoing other informatkon orthopedic procedures. If coadministration is essential, monitor patients closely 1 Dosage of fondaparinux sodium is expressed informagion terms of the salt. Optimal timing between administration of fondaparinux and neuraxial procedures not known.

Initial parenteral anticoagulants with established efficacy in patients with NSTE ACS include enoxaparin, heparin, bivalirudin only in patients managed with an early invasive strategyand fondaparinux.

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Bounameaux, H, Perneger T. Dosages for fondaparinux sodium and heparin, heparinoids, or LMWHs cannot be used interchangeably on a unit-for-unit or mg-for-mg basis 1 as they differ in the manufacturing process, anti-factor Xa and antithrombin activity, and dosage.


ACCP recommends fondaparinux as an option for thromboprophylaxis in acutely ill, hospitalized medical patients at increased risk of thrombosis.

Prevention of VTE in nonorthopedic surgical patients: Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.

Importance of advising patients who have had neuraxial anesthesia or spinal puncture to monitor for manifestations of spinal or epidural hematoma e. Risk also increased by history of traumatic or repeated epidural or spinal puncture, spinal deformity, or spinal surgery. Constipation, headache, insomnia, fever, nausea, urinary tract infection, coughing.

Importance of patients informing clinicians including dentists that they are receiving fondaparinux therapy before scheduling any invasive procedures.

Subscribe to receive email notifications whenever new articles are published.

Natural rubber-containing medical devices; user labeling. If PCI is performed while a patient is receiving fondaparinux, administer an additional anticoagulant with anti-factor IIa antithrombin activity because of arkxtra risk of catheter thrombosis.

Arixtra Monograph for Professionals –

Importance of informing patients that concomitant use of aspirin or other NSAIAs can increase risk of bleeding, and to discontinue use of these drugs whenever possible. Usual duration of therapy is 5—9 days, although up to 26 days of treatment has been used. Importance of women informing clinicians if they are or plan to become pregnant or plan arixtrs breast-feed.